Noninvasive optical bioluminescence imaging systems are important tools for evaluating gene expression in vivo for study of individual and temporal variation in a living animal. In this report, we demonstrate that expression of the firefly luciferase reporter gene (fl) delivered by transferrin (Tf) targeted polyethylenimine (PEI) complexes with, or without, poly(ethylene glycol) (PEG) modifications can be imaged in living A/J mice bearing N2A tumors using a cooled charged coupled device (CCD) camera. Tf-PEI-PEG, Tf-PEI, and PEI (positive control) complexes were tail-vein injected and mice were imaged at 5, 24, 48, and 72 h after complex injection. After imaging, the organs were analyzed ex vivo for firefly luciferase protein (FL) activity. The Tf and PEG modified formulations show significantly (Po0.05) higher FL activity in vivo and ex vivo at the tumor as compared to other organs, including the lungs (a site of high expression with PEI, the positive control). Furthermore, the in vivo bioluminescent signal correlated well (R 2 ¼0.83) with ex vivo FL activity. These data support that noninvasive imaging of fl reporter expression can be used to monitor the specificity of Tf-PEI and Tf-PEI-PEG polyplex targeting of N2A tumors in A/J mice.
Introduction
Gene therapy is the transfer of genetic material to correct the under-or overexpression of a protein. The most widely used methods of DNA transfer in vivo utilize viral and nonviral vectors like liposomes and polycations. Nonviral vectors are well known for lacking stable gene integration as well as low expression of the transfected genes in cells. For stable integration, longer lasting expression, or high expression, current technology is limited to the use of viral vectors. Viral gene delivery is more efficient than nonviral delivery, but nonviral vectors like DNA/polycation complexes (polyplexes) are less immunogenic, can be mass produced and shipped, and can be targeted to organs effectively. 1 The benefits of using these vectors can be best visualized in cancer therapies where targeted polycations can be engineered to carry a DNA cargo 2 or a chemotherapeutic. 3 Among the nonviral vectors, polyethylenimines (PEI) are known to exhibit efficient transfection properties in vivo owing to their ability to efficiently protonate, bind, protect, and deliver DNA in a favorable manner. 4, 5 To increase circulation efficiency and prevent complex entrapment in the reticuloendothelial system of the lungs, these molecules can be shielded with poly(ethylene) glycol (PEG) (Figure 1) . 6 This reduces nonspecific interactions with plasma proteins, like opsonins, that would identify the polycation as foreign. This modification also allows for stabilization, and therefore shipping, of the preformed complex. Intravenous injection of a PEGylated polyplex would result in passive accumulation of the polyplex in a tumor. However, to advance the beneficial effects of gene therapies, researchers have begun to target polycations in a noninvasive but directed manner 7, 8 by complexing polycations with antibodies, vitamins, glycolipids, and receptor ligands, like transferrin (Tf).
Tf has been evaluated as a targeting molecule on PEI complexes in mice using the firefly luciferase gene (fl) as a reporter to monitor gene delivery and expression. 6, 8 Previously, these studies have been done with invasive, ex vivo analysis of the resulting gene expression, but with the advent of new technologies it is now possible to monitor the expression of reporter genes in living animals. 9 In vivo monitoring of therapeutic gene delivery and expression can be accomplished by using optical reporter genes, like fl 10 and green fluorescent protein (GFP), 11 or radionuclide reporter systems using herpes simplex virus type I thymidine kinase (HSV1-tk) or the dopamine D 2 receptor. 12 We and others have shown that fl expression can be monitored in living animals using a cooled charge coupled device (CCD) camera, 13 -17 yet only one previous study has monitored liposomal reporter gene delivery utilizing a nontargeted delivery system. 18 The benefits of using optical CCD imaging are that it is noninvasive, allows for repeated studies in the same animal, permits high throughput screening of many gene delivery formulations, is relatively sensitive and is quantifiable.
In this study, we show that delivery of fl by CMV-fl DNA/PEI polyplexes and subsequent fl expression can be imaged in living mice using a cooled CCD camera. We use different PEI polycation formulations to look at how modifications of the simple PEI polycation with transferrin and PEG affect their biodistribution and the expression of fl using in vivo imaging. Further, we correlate the bioluminescent signal to the ex vivo firefly luciferase protein (FL) activity.
Results
In cell culture N2A cells show high transfection with polyplexes
We first evaluated the transfection efficiency of the PEI complexes in cell culture. N2A cells were incubated with the various polyplexes (the nomenclature and composition are listed in Table 1 ). With transfection of the fl reporter, there is significantly greater (Po0.01) FL activity as compared to the level of bioluminescence in the negative control (Tf-PEI-PEG-bgal) (Figure 2 ). PEI and Tf-PEI show equal transfection efficiency in N2A cells and higher transfection efficiencies than either Tf-PEI-PEG-A or Tf-PEI-PEG-B (Po0.01).
CCD imaging of living mice carrying N2A xenografts shows strongest fl expression in the tumor following injection of Tf CMV-fl DNA/PEI polyplexes To assess that the formulations are specifically targeting the tumor, various DNA/PEI polyplexes were administered intravenously into mice bearing subcutaneous N2A tumors and fl expression was measured by optical imaging with a cooled CCD camera. Minimal background CCD signals (less than 60 RLU/min, near the average background observed) are seen in animals treated with Tf-PEI-PEG-bgal (negative control, n¼2) (data not shown). We observe significantly (Po0.05) high levels of fl expression in the lungs upon injection of PEI (positive control) complexes, which is clearly visible with both supine and prone imaging positions (Figure 3a , prone position only). Owing to the relatively strong FL expression detected in the lungs of PEI-treated animals, we can only discern expression in the tumor when tumors are placed near the hind limbs. In contrast, the Tf-and PEG-containing formulations show appreciably higher than background fl expression at the tumor region in comparison to the lungs. The gene expression and resulting signal intensity is comparable between complex formulations (Figure 3b ). In addition, the cooled CCD camera is able to detect substantial fl expression in the tail and higher than background levels of fl expression in the liver in Tf-PEI-treated animals (not shown). No significant bioluminescence is detectable in other organs with any formulation.
Intensity of the bioluminescent CCD signal is enhanced with an increase in the administered D-luciferin dose
In comparison to other vectors used in our laboratory to image fl expression, the intensity of the bioluminescent signal using the polyplexes is observed to be relatively The difference in charge ratio between anionic DNA and cationic polymer leads to a complex that has a net positive charge which can be shielded with modifications like transferrin, for targeting of the complex to specific sites like tumors, and/or PEG to further prevent interactions with plasma and blood components. To determine if the bioluminescence detected is being emitted from the tumor versus other organs, all organs (including the tail and tumor) were analyzed ex vivo for FL activity. In PEI-treated animals (n¼4), FL activity is detectable in all organs and lung expression (397872694 RLU/mg protein/min) is nearly 100 times greater than tumor expression (46721 RLU/mg protein/ min) (data not shown). Tf-PEI, Tf-PEI-PEG-A, and Tf-PEI-PEG-B injected mice show the highest levels of FL activity in the tumor in comparison to other organs (Figure 5a-c) . The tail often displays high activity comparable to the tumor activity, which could be because of variations in technique of the tail vein injection of the complexes. In the ex vivo analysis of the organs of Tf-PEItreated mice, we observe low levels of FL activity in the liver and lung (both are less than 1 RLU/mg protein/ min) and these levels are not significant when compared to activity in the tumor (Po0.05, ANOVA).
In vivo CCD signal correlates well with ex vivo FL activity in the tumors
To verify that the bioluminescent signal detected in the tumor in vivo is indicative of FL activity in the tumor detected ex vivo, mice injected with Tf-PEI, Tf-PEI-PEG-A, and Tf-PEI-PEG-B (total, n¼30) were scanned (with 2 Â D-luciferin) and killed at 24 or 48 postpolycation injection. The data show a strong correlation between the bioluminescent signal detected by CCD imaging and ex vivo quantification of FL activity (2 Â : R 2 ¼0.83, Figure 6 ).
fl expression in N2A tumors follows time dependant kinetics
Optical imaging using a cooled CCD camera allows for fl expression to be monitored repeatedly over time ( Figure  7 ). To assess fl expression, animals were imaged at 5, 24, 48, and 72 h postinjection of the complex ( Figure 7 and Table 2 ). For example, in Tf-PEI-PEG-A animals, fl expression is maximal at 24 h then decreases over 48 and 72 h ( Figure 7) . A similar pattern is seen with the other polyplex formulations, Tf-PEI and Tf-PEI-PEG-B (Table 2) .
Discussion
It has previously been demonstrated by us and others that noninvasive optical imaging techniques can be used to monitor the expression of optical reporter genes. [13] [14] [15] [16] [17] 19, 20 Firefly luciferase gene expression has been monitored in transfected cell implants 19, 20 and after delivery by viral vectors. 14, 16 Recently, Iyer et al 18 have shown the first example of bioluminescent imaging of liposomal gene delivery, but polycationic gene delivery using a targeted vector complex has not been documented.
Whole-body bioluminescent imaging is becoming an important technique to investigate many animal models. Among the merits of optical imaging is that gene expression can be monitored quantitatively and noninvasively. Schuetz et al 21 has stressed that optical bioluminescent imaging can be used as 'a real-time in vivo transcription assay'. Our specific aim was to use optical imaging to follow delivery of fl by a targeted nonviral, polycationic gene delivery vector. Transferrintargeted DNA/PEI polyplexes have previously been Optical imaging of polycation gene delivery in mice IJ Hildebrandt et al described to successfully deliver transgenes to distant N2A tumors, but used methods that solely involved killing of animals. 8, 22 Using noninvasive optical imaging, we have shown for the first time that polycationictargeted gene delivery to tumor sites can be monitored non-invasively and repetitively using a cooled CCD camera. At 24 h after injection of Tf-DNA/PEI polyplex formulations, fl expression is detected at the tumor site. The kinetics of gene expression changes with time, depending on the type of polyplex used. Gene expression in the lungs of the positive control (PEI) animals is significantly higher than in animals that received the modified formulations. Modification of the complex with Tf or Tf-PEG allows for longer circulation of the complexes and prevents the polyplexes from getting trapped in the reticuloendothelial system of the lungs thus promoting targeted gene delivery to the tumor. Changes in fl expression in the same mouse can be followed over a period of 5 days, and increasing the administered D-luciferin dose enhances detection of fl expression in the tumor. Additional studies are underway in our laboratory to investigate the dosing effects of D-luciferin in this and other models that use fl as a reporter. We are also validating more sensitive optical repoter genes such as a synthetic renilla luciferase, which should lead to a log order more sensitivity. 20 With continued improvement in sensitivity of detection, formulations with very low efficiency should be able to be utilized with noninvasive optical CCD imaging. This is the first study to directly compare these PEI formulations. The size of the covalently attached PEG (20 versus 40 kDa) did not seem to significantly affect tumor targeting. In the living animal, these modifications could work against each other. PEG and Tf can increase the likelihood of transfection by prolonging circulation halflife in the blood, yet decrease the ability of the complex to transfect the cells. This is because the extra PEG shielding results in nearly uncharged polyplex, a state that may inhibit polyplex/cell interaction, even with Tfmediated endocytosis. 6 There has been continual development and improvement of a number of PEI polyplexes to be used as gene therapy agents. It has been established Optical imaging of polycation gene delivery in mice IJ Hildebrandt et al that PEGylation of Tf-PEI complexes significantly increased the circulation time 6 and that the presence of Tf or PEG prevents erythrocyte aggregation, a known factor in systemic toxicity, which could prevent delivery to the target organ.
6,8 Although we did not investigate the biological half-lives of the reagents used, previous studies have investigated many similar formulations. 6, 8, [23] [24] [25] Two of the vectors that we used (Tf-PEI-PEG-A and B) have not been published yet in regard to all of the biological parameters, but analysis regarding zeta potentials, polyplex size, erythrocyte aggregation, half-life in the plasma and blood, and DNA distribution are being investigated. The main benefit of these PEG containing formulations is that they can be complexed with DNA and shipped/stored while retaining activity that is comparable to the non-PEGylated formulation.
The relatively low and variable in vivo transfection efficiency could be because of a number of other factors, including injection variability, tumor vascularization/ heterogeneity, and degradation of the polyplex. Although polycation/DNA complex injection was done when the tumors were in the same size range, differences in vascularization and tumor heterogeneity are likely to exist. Multiple animals were injected with formulations that were prepared and used on the same day. Furthermore, in a preliminary experiment, we injected Tf-PEI complexes into mice with two N2A tumors and found that there was equal and relatively high expression in both tumors (data not shown), indicating that it is not a lack of complex availability that limits expression.
In conclusion, the targeting of DNA/PEI polyplexes can be monitored by using a combination of in vivo techniques to follow fl delivery and expression. The transferrin receptor is very ubiquitous among cell types, therefore the use of transferrin as a targeting molecule may not be the best method for targeting specific cell types in vivo. Other molecules have been investigated for targeting gene delivery formulations like folate, specific antibodies, and epidermal growth factor 26 that may represent more specific targeted vector combinations.
Ultimately, gene delivery and expression will be monitored completely noninvasively, but improvements in reporter gene sensitivity and delivery will be needed. Noninvasive bioluminescent imaging in living subjects offers a method for rapid and easy investigation into a variety of different animal models that will be improved by utilizing more sensitive reporter genes. Overall, noninvasive imaging allows for insight into variation in individual living animals under normal physiological conditions. Furthermore, noninvasive imaging allows for high throughput screening and data collecting of subjects. Polycation/DNA complexes PEI polycation components were complexed with plasmids contatining a CMV promoter and coding for fl or the b-galactosidase gene (bgal). 6, 8 The composition of the polyplex formulations is described in Table 1 . The complexes, Tf-PEI-PEG-A, Tf-PEI-PEG-B, and PEGTf-PEI-bgal, prepared at PEI nitrogen to DNA phosphate ratio (N/P) of 6, were adjusted to 5% glucose to insure iso-osmolarity before using. The Tf-PEI and PEI complexes were prepared by diluting the PEI (22) or Tf-PEI(25) components in buffer (for Tf-PEI: 20 mM HEPES, pH 7.3 and 75 mM NaCl; for PEI: 20 mM HEPES, pH 7.3). The PEI components were then mixed with 100 mg DNA and incubated at room temperature for 20 min. The complexes were adjusted to 2.5% glucose (Tf-PEI) or 5% glucose (PEI).
Materials and methods

Cell culture transfections
N2A (Murine Neuro2A neuroblastoma, a gift from Scripps Institute, La Jolla, CA, USA) cells were cultured in DMEM, supplemented with 10% FBS and 1% penicillin and streptomycin solution. Transfection complexes were prepared as described above. At 24 h before transfection, cells were plated in six-well plates (in triplicate) at 3 Â 10 5 cells per well. For each transfection, 2 mg DNA in complete media was added to cells after washing with PBS. After a 2.5 h incubation at 371C, the cells were washed with PBS and 2 ml of complete media were added; 24 h later, the cells were harvested and assayed for FL activity. 14, 19 The results were expressed as RLU normalized to milligram of protein per minute.
In vivo PEI/DNA polyplex delivery to tumor bearing mice Animal handling and procedures were approved by the UCLA Animal Research Committee. Syngenic A/J mice (6-8 weeks, female) were purchased from Harlan Sprague-Dawley (Indianapolis, IN, USA). The mice were injected subcutaneously with 1-2 Â 10 6 N2A cells near the forelimbs or hindlimbs. Tumor placement varied to help differentiate lung signal from tumor signal and to prevent artifacts owing to tumor placement. After 10-14 days, when tumors had reached 8-14 mm in diameter, the animals were injected intravenously via the tail vein, with 250 ml of the transfection complex (containing 50 mg DNA). At 24 and 48 h postpolyplex injection, animals were imaged in vivo and then killed for ex vivo analysis of FL activity.
In vivo CCD camera imaging of fl reporter gene expression
Animals were imaged at 5, 24, 48, and/or 72 h after a single systemic delivery of the polyplexes. For imaging, the animals were anesthetized with 20 ml of a 4 : 1 ketamine : xylaxine mixture (i.p.). At 5 min after receiving anesthesia, the animals were injected i.p. with 200 ml of D-luciferin (Xenogen, Alameda CA, USA) at 15 mg/ml (1 Â or 3 mg/mouse) or 30 mg/ml (2 Â or 6 mg/mouse) depending on the experiment. Before imaging, the hair over the tumor was shaved to minimize photon attenuation. After 10 min, when peak levels of bioluminescent light production occur, 14 the animals were placed in the imaging chamber of the Xenogen IVIS system, which includes a cooled CCD camera. A gray scale photograph of the animals was acquired, followed by a 5 min prone, a 15 min prone, and a 5 min supine position bioluminescent acquisition. Regions of interest (ROIs) were drawn over the positions of greatest intensity signal on the animal, as well as over regions of 'no' signal, to 
Ex vivo determination of FL activity
After imaging at 24 and 48 h postinjection, the animals were killed. The heart, lungs, liver, kidney, spleen, tail, and tumor were harvested and analyzed ex vivo using a procedure previously described 14, 19 with a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA) and a 10 s integration time. The RLU obtained was normalized to milligram of protein per minute.
All data are reported as mean7s.e.m. Statistical evaluation was performed using ANOVA or two-tailed, unpaired, unequal variance Student's t-test; Po0.05 is considered significant.
